150 related articles for article (PubMed ID: 38614827)
1. Imaging and Liquid Biopsy for Distinguishing True Progression From Pseudoprogression in Gliomas, Current Advances and Challenges.
Li K; Zhu Q; Yang J; Zheng Y; Du S; Song M; Peng Q; Yang R; Liu Y; Qi L
Acad Radiol; 2024 Apr; ():. PubMed ID: 38614827
[TBL] [Abstract][Full Text] [Related]
2. Clinical Imaging for Diagnostic Challenges in the Management of Gliomas: A Review.
Bonm AV; Ritterbusch R; Throckmorton P; Graber JJ
J Neuroimaging; 2020 Mar; 30(2):139-145. PubMed ID: 31925884
[TBL] [Abstract][Full Text] [Related]
3. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.
de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S
J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754
[TBL] [Abstract][Full Text] [Related]
4. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.
Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S
NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862
[TBL] [Abstract][Full Text] [Related]
5. Low-parameter supervised learning models can discriminate pseudoprogression and true progression in non-perfusion-based MRI.
Warner E; Lee J; Krishnan S; Wang N; Mohammed S; Srinivasan A; Bapuraj J; Rao A
Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-4. PubMed ID: 38083692
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma.
Verma G; Chawla S; Mohan S; Wang S; Nasrallah M; Sheriff S; Desai A; Brem S; O'Rourke DM; Wolf RL; Maudsley AA; Poptani H
NMR Biomed; 2019 Feb; 32(2):e4042. PubMed ID: 30556932
[TBL] [Abstract][Full Text] [Related]
7. Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review.
Sidibe I; Tensaouti F; Roques M; Cohen-Jonathan-Moyal E; Laprie A
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203493
[TBL] [Abstract][Full Text] [Related]
8. Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas.
Ma B; Blakeley JO; Hong X; Zhang H; Jiang S; Blair L; Zhang Y; Heo HY; Zhang M; van Zijl PC; Zhou J
J Magn Reson Imaging; 2016 Aug; 44(2):456-62. PubMed ID: 26788865
[TBL] [Abstract][Full Text] [Related]
9. Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis.
Sidibe I; Tensaouti F; Gilhodes J; Cabarrou B; Filleron T; Desmoulin F; Ken S; Noël G; Truc G; Sunyach MP; Charissoux M; Magné N; Lotterie JA; Roques M; Péran P; Cohen-Jonathan Moyal E; Laprie A
Radiother Oncol; 2023 Apr; 181():109486. PubMed ID: 36706959
[TBL] [Abstract][Full Text] [Related]
10. Perfusion magnetic resonance imaging in the differentiation between glioma recurrence and pseudoprogression: a systematic review, meta-analysis and meta-regression.
Zhang J; Wang Y; Wang Y; Xiao H; Chen X; Lei Y; Feng Z; Ma X; Ma L
Quant Imaging Med Surg; 2022 Oct; 12(10):4805-4822. PubMed ID: 36185045
[TBL] [Abstract][Full Text] [Related]
11. A deep learning model for discriminating true progression from pseudoprogression in glioblastoma patients.
Moassefi M; Faghani S; Conte GM; Kowalchuk RO; Vahdati S; Crompton DJ; Perez-Vega C; Cabreja RAD; Vora SA; Quiñones-Hinojosa A; Parney IF; Trifiletti DM; Erickson BJ
J Neurooncol; 2022 Sep; 159(2):447-455. PubMed ID: 35852738
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
[TBL] [Abstract][Full Text] [Related]
13. Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Lee WJ; Choi SH; Park CK; Yi KS; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH
Acad Radiol; 2012 Nov; 19(11):1353-61. PubMed ID: 22884399
[TBL] [Abstract][Full Text] [Related]
14. Retrospective examination of pseudoprogression in
Wetzel EA; Farrell MJ; Eldred BSC; Liu V; Saha I; Zapanta Rinonos S; Prins T; Li T; Cao M; Hegde J; Kaprealian T; Khanlou N; Liau LM; Nghiemphu PL; Cloughesy TF; Chong RA; Ellingson BM; Lai A
Neurooncol Adv; 2023; 5(1):vdad028. PubMed ID: 37128507
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma.
El-Abtah ME; Talati P; Fu M; Chun B; Clark P; Peters A; Ranasinghe A; He J; Rapalino O; Batchelor TT; Gilberto Gonzalez R; Curry WT; Dietrich J; Gerstner ER; Ratai EM
Neurooncol Adv; 2022; 4(1):vdac128. PubMed ID: 36071927
[TBL] [Abstract][Full Text] [Related]
16. Differentiation Between True Tumor Progression of Glioblastoma and Pseudoprogression Using Diffusion-Weighted Imaging and Perfusion-Weighted Imaging: Systematic Review and Meta-analysis.
Tsakiris C; Siempis T; Alexiou GA; Zikou A; Sioka C; Voulgaris S; Argyropoulou MI
World Neurosurg; 2020 Dec; 144():e100-e109. PubMed ID: 32777397
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of glioma pseudoprogression identification with positron emission tomography imaging: a systematic review and meta-analysis.
Ouyang ZQ; Zheng GR; Duan XR; Zhang XR; Ke TF; Bao SS; Yang J; He B; Liao CD
Quant Imaging Med Surg; 2023 Aug; 13(8):4943-4959. PubMed ID: 37581048
[TBL] [Abstract][Full Text] [Related]
18. Tumor Progression and Treatment-Related Changes: Radiological Diagnosis Challenges for the Evaluation of Post Treated Glioma.
Qin D; Yang G; Jing H; Tan Y; Zhao B; Zhang H
Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954435
[TBL] [Abstract][Full Text] [Related]
19. Pseudoprogression after glioma therapy: an update.
Galldiks N; Kocher M; Langen KJ
Expert Rev Neurother; 2017 Nov; 17(11):1109-1115. PubMed ID: 28862482
[TBL] [Abstract][Full Text] [Related]
20. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
